About Altheia Science
Altheia Science is a company based in Milan (Italy) founded in 2017. It operates as a HealthTech. Altheia Science has raised $19.32 million across 1 funding round from investors including Rottapharm Biotech and Fin Posillipo. Altheia Science offers products and services including Cell and Gene Therapies. Altheia Science operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Milan, Italy
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Altheia Science Srl
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$19.32 M (USD)
in 1 rounds
-
Latest Funding Round
$19.32 M (USD), Series A
Sep 25, 2018
-
Investors
Rottapharm Biotech
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Altheia Science
Altheia Science offers a comprehensive portfolio of products and services, including Cell and Gene Therapies.
Innovative therapies are developed for autoimmune disease treatment.
Funding Insights of Altheia Science
Altheia Science has successfully raised a total of $19.32M through 1 strategic funding round. The most recent funding activity was a Series A round of $19.32 million completed in September 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Altheia Science
Altheia Science has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Rottapharm Biotech and Fin Posillipo.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Discovers and develops novel drugs via internal research and external partnerships.
|
Locked | Locked | Locked | |
|
Fin Posillipo is engaged in investment for innovation and leadership.
|
Locked | Locked | Locked |
Investor details for Altheia Science
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Altheia Science
Investment portfolio details for Altheia Science
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Altheia Science
Detailed financials for Altheia Science
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Altheia Science Comparisons
Peer comparison for Altheia Science
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Altheia Science
Altheia Science operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
Detailed competitors of Altheia Science
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Altheia Science
Complete news archive for Altheia Science
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Altheia Science
Altheia Science was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Altheia Science is headquartered in Milan, Italy. It is registered at Milan, Lombardy, Italy.
Altheia Science is a funded company, having raised a total of $19.32M across 1 funding round to date.
Altheia Science is focused on transforming patient lives through the development of curative cell and gene therapies. The company targets autoimmune diseases with innovative solutions. Research and technology are leveraged to create impactful treatments in the healthcare sector. Operations are based in Italy and the USA to support global outreach.
Altheia Science's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Altheia Science offers Cell and Gene Therapies.
Altheia Science has 2 investors. Key investors include Rottapharm Biotech, and Fin Posillipo.